Targeted delivery of glycine receptors to excitable cells
The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous GlyR protein (an ion channel) in response to the allosteric modulator modulates the electrophysiological activity of the excitable cell. The method can be used to control pain in a subject. The invention further provides a replication-defective HSV vector comprising an expression cassette encoding a GlyR protein, stocks and pharmaceutical compositions containing such vectors, and a transgenic animal.
1. A method of attenuating the sensation of pain in a subject, comprising causing exogenous expression of a glycine receptor alpha 1 (GlyRα1) protein in a peripheral neuron of a subject by introducing a genetic vector into the peripheral neuron, the vector comprising a nucleic acid encoding the GlyRα1 protein in operable linkage to a promoter, to express the GlyRαl protein in the peripheral neuron wherein the peripheral neuron is associated with the sensation of pain, and subsequently exposing the peripheral neuron to an agonist of the GlyRα1 protein.
2. The method of claim 1 , wherein the promoter is a constitutive promoter, an inducible promoter, or a cell-specific promoter.
3. The method of claim 1 , wherein the genetic vector is an AAV based vector.
4. The method of claim 1 , wherein the genetic vector is a replication-defective HSV vector.
5. The method of claim 1 , wherein the agonist comprises glycine.
6. The method of claim 1 , wherein the agonist comprises ivermectin.
7. The method of claim 1 , wherein the subject is human.
8. The method of claim 1 , wherein the GlyRα1 protein comprises a mutein of the GlyRα1 subunit.
9. The method of claim 8 , wherein the mutein has altered sites for zinc potentiation or zinc inhibition, anesthetic potentiation, or affinity for an agonist of the mutein.
10. The method of claim 8 , wherein the mutein exhibits altered sensitivity and/or selectivity for an agonist of the mutein.
11. The method of claim 8 , wherein the mutein exhibits altered affinity for an agonist of the mutein.
12. The method of claim 11 , wherein the agonist comprises ivermectin.
13. The method of claim 1 , wherein the method reduces regional sensation of pain.